Factors associated with Quitline and pharmacotherapy utilisation among low-socioeconomic status smokers.


Journal

Addictive behaviors
ISSN: 1873-6327
Titre abrégé: Addict Behav
Pays: England
ID NLM: 7603486

Informations de publication

Date de publication:
02 2019
Historique:
received: 24 03 2018
revised: 19 09 2018
accepted: 24 09 2018
pubmed: 6 10 2018
medline: 28 4 2020
entrez: 6 10 2018
Statut: ppublish

Résumé

To examine factors associated with Quitline and pharmacotherapy utilisation in low socioeconomic status (low-SES) smokers enrolled in a smoking cessation trial. Baseline data was used from a large-scale smoking cessation randomised controlled trial (RCT). Logistic regression models were used to examine predictors of treatment utilisation prior to entering the RCT and perceived effectiveness of past and future use. A total of 1047 smokers consented and prior to enrolment 92% had previously tried to quit smoking, 86% had ever used quit support, 83% had used pharmacotherapy at least once and 38% had ever utilised Quitline. For those who had used pharmacotherapies, 71% used NRT, of which 21% had used dual NRT products. In the last 12-months, 27% utilised Quitline and 50% utilised NRT. Ever use of Quitline was negatively associated with self-efficacy to quit (OR: 0.80; 95% CI: 0.68, 0.94 p < .01) and positively associated with being diagnosed with a mental health condition (OR: 1.50; 95% CI: 1.01, 2.25 p < .05). Recent use of NRT was positively associated with mental health condition (OR: 1.39; 95% CI: 1.02, 1.90 p < .05) and negatively associated with alcohol consumption (OR: 0.69; 95% CI: 0.52, 0.92 p < .01). Past use of Quitline and pharmacotherapy treatment was associated with self-efficacy to quit, sociodemographic variables, mental health conditions and alcohol consumption. Community-based strategies that target smoking, mental health and drug and alcohol problems may overcome some of the barriers that prevent low-SES populations from engaging with smoking cessation support.

Identifiants

pubmed: 30290299
pii: S0306-4603(18)30219-3
doi: 10.1016/j.addbeh.2018.09.029
pii:
doi:

Types de publication

Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

113-120

Informations de copyright

Copyright © 2018 Elsevier Ltd. All rights reserved.

Auteurs

Veronica C Boland (VC)

University of New South Wales (UNSW), National Drug and Alcohol Research Centre (NDARC), 22-32 King Street, Randwick, New South Wales 2031, Australia. Electronic address: v.boland@unsw.edu.au.

Richard P Mattick (RP)

University of New South Wales (UNSW), National Drug and Alcohol Research Centre (NDARC), 22-32 King Street, Randwick, New South Wales 2031, Australia.

Mohammad Siahpush (M)

Department of Health Promotion, Social and Behavioral Health, University of Nebraska Medical Center, Omaha, NE, USA.

Daniel Barker (D)

School of Medicine & Public Health, University of Newcastle, Newcastle, Australia.

Christopher M Doran (CM)

Centre for Indigenous Health Equity Research, Central Queensland University, 160 Ann Street, Brisbane, Queensland 4000, Australia.

Kristy A Martire (KA)

School of Psychology, The University of New South Wales, Sydney, Australia.

Billie Bonevski (B)

School of Medicine & Public Health, University of Newcastle, Newcastle, Australia.

Hayden McRobbie (H)

Wolfson Institute of Preventive Medicine, Queen Mary University of London, EC1M 6BQ, London, UK.

Ron Borland (R)

Centre for Behavioural Research in Cancer, Cancer Council Victoria, Melbourne, Australia.

Michael Farrell (M)

University of New South Wales (UNSW), National Drug and Alcohol Research Centre (NDARC), 22-32 King Street, Randwick, New South Wales 2031, Australia.

Robert West (R)

Health Behaviour Research Centre, Department of Epidemiology and Public Health, University College London, United Kingdom.

Ryan J Courtney (RJ)

University of New South Wales (UNSW), National Drug and Alcohol Research Centre (NDARC), 22-32 King Street, Randwick, New South Wales 2031, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH